TENAYA
E827013
TENAYA is a Phase III clinical trial evaluating the efficacy and safety of faricimab for the treatment of neovascular (wet) age-related macular degeneration.
All labels observed (1)
| Label | Occurrences |
|---|---|
| TENAYA canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T9807334 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: TENAYA Context triple: [faricimab, clinicalTrial, TENAYA]
-
A.
La Plata Peak
La Plata Peak is one of Colorado's highest mountains and a popular "fourteener" in the Sawatch Range, known for its rugged terrain and scenic alpine views.
-
B.
Toro Peak
Toro Peak is a prominent mountain summit in Southern California known for its high elevation and expansive desert and mountain views.
-
C.
La Cumbre Peak
La Cumbre Peak is a prominent summit overlooking Santa Barbara, California, known for its panoramic views of the Pacific Ocean and the surrounding coastal mountains.
-
D.
Cahuenga Peak
Cahuenga Peak is a prominent summit in the Hollywood Hills of Los Angeles, known for its hiking trails, panoramic city views, and proximity to the Hollywood Sign.
-
E.
Gray Peak
Gray Peak is one of the Adirondack High Peaks in New York’s Adirondack Mountains, known for its remote, trailless ascent and proximity to Mount Marcy.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: TENAYA Target entity description: TENAYA is a Phase III clinical trial evaluating the efficacy and safety of faricimab for the treatment of neovascular (wet) age-related macular degeneration.
-
A.
La Plata Peak
La Plata Peak is one of Colorado's highest mountains and a popular "fourteener" in the Sawatch Range, known for its rugged terrain and scenic alpine views.
-
B.
Toro Peak
Toro Peak is a prominent mountain summit in Southern California known for its high elevation and expansive desert and mountain views.
-
C.
La Cumbre Peak
La Cumbre Peak is a prominent summit overlooking Santa Barbara, California, known for its panoramic views of the Pacific Ocean and the surrounding coastal mountains.
-
D.
Cahuenga Peak
Cahuenga Peak is a prominent summit in the Hollywood Hills of Los Angeles, known for its hiking trails, panoramic city views, and proximity to the Hollywood Sign.
-
E.
Gray Peak
Gray Peak is one of the Adirondack High Peaks in New York’s Adirondack Mountains, known for its remote, trailless ascent and proximity to Mount Marcy.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
Phase III clinical trial
ⓘ
clinical trial ⓘ ophthalmology clinical trial ⓘ |
| allocation | randomized ⓘ |
| comparison | faricimab versus aflibercept ⓘ |
| conditionCategory | age-related macular degeneration ⓘ |
| controlTreatment | aflibercept ⓘ |
| developerOfInvestigationalDrug |
Genentech
ⓘ
Roche ⓘ |
| drugClass | bispecific antibody ⓘ |
| drugMechanism | dual inhibition of VEGF-A and Ang-2 ⓘ |
| drugTarget |
Angiopoietin-2
ⓘ
VEGF-A ⓘ
linked to:
vascular endothelial growth factor A
|
| evaluates | faricimab ⓘ |
| evaluatesEfficacyOf | faricimab ⓘ |
| evaluatesSafetyOf | faricimab ⓘ |
| geographicScope | multinational ⓘ |
| indication |
neovascular age-related macular degeneration
ⓘ
wet age-related macular degeneration ⓘ |
| indicationAbbreviation | nAMD ⓘ |
| investigationalDrug | faricimab ⓘ |
| masking | double-masked ⓘ |
| objective | to demonstrate non-inferiority of faricimab to aflibercept in nAMD ⓘ |
| outcomeMeasure |
anatomical retinal outcomes
ⓘ
safety and tolerability ⓘ visual acuity outcomes ⓘ |
| phase | Phase III ⓘ |
| population | adult patients ⓘ |
| primaryEndpoint | change in best-corrected visual acuity at one year ⓘ |
| primaryEndpointType | efficacy ⓘ |
| registrationDatabase | ClinicalTrials.gov ⓘ |
| relatedTrial | LUCERNE ⓘ |
| resultsSupport | approval of faricimab for nAMD in multiple regions ⓘ |
| routeOfAdministration | intravitreal injection ⓘ |
| secondaryEndpointType | safety ⓘ |
| sponsor |
Genentech
ⓘ
Roche ⓘ |
| sponsorType | industry ⓘ |
| therapeuticArea |
ophthalmology
ⓘ
retinal disease ⓘ |
| treats |
neovascular age-related macular degeneration
ⓘ
wet age-related macular degeneration ⓘ |
| trialDesign |
active-controlled
ⓘ
double-masked ⓘ randomized ⓘ |
| trialStatus | completed ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: TENAYA Description of subject: TENAYA is a Phase III clinical trial evaluating the efficacy and safety of faricimab for the treatment of neovascular (wet) age-related macular degeneration.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.